このエントリーをはてなブックマークに追加
ID 55587
JaLCDOI
フルテキストURL
Thumnail 71_6_505.pdf 3.21 MB
著者
Honda, Yoshihiro Department of Allergy and Respiratory Medicine, Okayama University Hospital
Takigawa, Nagio Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ichihara, Eiki Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ninomiya, Takashi Department of Allergy and Respiratory Medicine, Okayama University Hospital
Kubo, Toshio Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ochi, Nobuaki Department of Allergy and Respiratory Medicine, Okayama University Hospital
Yasugi, Masayuki Department of Allergy and Respiratory Medicine, Okayama University Hospital
Murakami, Toshi Department of Allergy and Respiratory Medicine, Okayama University Hospital
Yamane, Hiromichi General Internal Medicine 4, Kawasaki Medical School
Tanimoto, Mitsune Department of Allergy and Respiratory Medicine, Okayama University Hospital
Kiura, Katsuyuki Department of Allergy and Respiratory Medicine, Okayama University Hospital
抄録
(−)-Epigallocatechin-3-gallate (EGCG) has been shown to bind to several receptors including epidermal growth factor receptor (EGFR). EGFR tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK) inhibitors are effective for non-small cell lung cancers harboring activating EGFR mutations and ALK or c-ros oncogene 1 (ROS1) fusion genes, respectively. We investigated the effects of EGCG on EGFR- or fusion gene-driven lung cancer cells such as PC-9, RPC-9, H1975, H2228 and HCC78. The five cell lines had similar sensitivity to EGCG. Phosphorylated (p)EGFR, pAkt and pErk in PC-9, RPC-9 and H1975 cells were suppressed by EGCG (50 or 100 μM). EGCG also inhibited pALK in H2228, pROS1 in HCC78, and pErk and pAkt in both cell lines. All the xenograft tumors established using the 5 cell lines in EGCG-treated groups were significantly smaller than the tumors in the vehicle-treated groups. The numbers of tumor blood vessels of xenograft tissues in EGCG-treated mice were significantly lower than those in vehicle-treated mice. In conclusion, EGCG may be effective for EGFR-driven lung tumors irrespective of the presence of T790M, and for ALK or ROS1 fusion gene-driven lung tumors.
キーワード
epigallocatechin-3-gallate
lung cancer
EGFR
ALK
ROS1
Amo Type
Original Article
発行日
2017-12
出版物タイトル
Acta Medica Okayama
71巻
6号
出版者
Okayama University Medical School
開始ページ
505
終了ページ
512
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
著作権者
CopyrightⒸ 2017 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID